The Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue Plasminogen Activator ( rt-PA ) in Acute Ischemic Stroke-Enhanced Regimen ( CLEAR-ER ) trial found that intravenous rt-PA plus eptifibatide ( combination arm ) in acute ischemic stroke ( AIS ) was safe and had a direction of effect that would justify a phase III trial .